S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NYSE:GKOS

Glaukos Stock Forecast, Price & News

$45.50
-3.04 (-6.26%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$44.79
$47.91
50-Day Range
$42.78
$56.99
52-Week Range
$42.69
$99.00
Volume
351,332 shs
Average Volume
517,325 shs
Market Capitalization
$2.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.66
30 days | 90 days | 365 days | Advanced Chart
Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.


Glaukos logo

About Glaukos

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Headlines

Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3
November 8, 2021 |  finance.yahoo.com
Glaukos (NYSE:GKOS) Trading Down 3.5%
November 8, 2021 |  americanbankingnews.com
Glaukos Corp (GKOS) Q3 2021 Earnings Call Transcript
November 7, 2021 |  finance.yahoo.com
Piper Sandler Boosts Glaukos (NYSE:GKOS) Price Target to $55.00
November 5, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
653
Year Founded
N/A

Sales & Book Value

Annual Sales
$224.96 million
Cash Flow
$0.31 per share
Book Value
$12.82 per share

Profitability

Net Income
$-120.35 million
Pretax Margin
-13.92%

Debt

Price-To-Earnings

Miscellaneous

Free Float
42,857,000
Market Cap
$2.13 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

974th out of 1,392 stocks

Surgical & Medical Instruments Industry

97th out of 125 stocks

Analyst Opinion: 2.9Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Glaukos (NYSE:GKOS) Frequently Asked Questions

Is Glaukos a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos
or view top-rated stocks.

How has Glaukos' stock price been impacted by COVID-19?

Glaukos' stock was trading at $38.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GKOS shares have increased by 17.8% and is now trading at $45.50.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Glaukos?

Glaukos saw a decline in short interest in the month of October. As of October 15th, there was short interest totaling 1,350,000 shares, a decline of 31.5% from the September 30th total of 1,970,000 shares. Based on an average daily trading volume, of 579,900 shares, the short-interest ratio is currently 2.3 days. Currently, 3.0% of the company's shares are short sold.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Glaukos
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) issued its earnings results on Thursday, November, 4th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.37. The medical instruments supplier earned $74.71 million during the quarter, compared to the consensus estimate of $72.73 million. Glaukos had a negative net margin of 13.05% and a negative trailing twelve-month return on equity of 4.12%. The company's quarterly revenue was up 15.2% on a year-over-year basis. During the same period last year, the business earned ($0.09) earnings per share.
View Glaukos' earnings history
.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $285 million-$290 million, compared to the consensus revenue estimate of $287.86 million.

What price target have analysts set for GKOS?

9 Wall Street analysts have issued twelve-month target prices for Glaukos' stock. Their forecasts range from $34.00 to $105.00. On average, they anticipate Glaukos' share price to reach $58.56 in the next year. This suggests a possible upside of 28.7% from the stock's current price.
View analysts' price targets for Glaukos
or view top-rated stocks among Wall Street analysts.

Who are Glaukos' key executives?

Glaukos' management team includes the following people:
  • Thomas William Burns, President, Chief Executive Officer & Director
  • Chris M. Calcaterra, Chief Operating Officer
  • Joseph E. Gilliam, CFO, CAO & Senior VP-Corporate Development (LinkedIn Profile)
  • L. Jay Katz, Chief Medical Officer
  • Tomas Navratil, Senior Vice President-Research & Development

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (8.10%), Baillie Gifford & Co. (4.34%), Artisan Partners Limited Partnership (3.46%), Janus Henderson Group PLC (3.33%), Geode Capital Management LLC (1.61%) and Marshall Wace LLP (1.43%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos
.

Which institutional investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Macquarie Group Ltd., New York State Common Retirement Fund, Artisan Partners Limited Partnership, Bellevue Group AG, Dimensional Fund Advisors LP, Citigroup Inc., and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and William J Phd Link.
View insider buying and selling activity for Glaukos
or view top insider-selling stocks.

Which institutional investors are buying Glaukos stock?

GKOS stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Marshall Wace LLP, Balyasny Asset Management LLC, Renaissance Technologies LLC, Voloridge Investment Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, and Healthcare of Ontario Pension Plan Trust Fund.
View insider buying and selling activity for Glaukos
or or view top insider-buying stocks.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $45.50.

How much money does Glaukos make?

Glaukos has a market capitalization of $2.13 billion and generates $224.96 million in revenue each year. The medical instruments supplier earns $-120.35 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Glaukos have?

Glaukos employs 653 workers across the globe.

What is Glaukos' official website?

The official website for Glaukos is www.glaukos.com.

Where are Glaukos' headquarters?

Glaukos is headquartered at 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at [email protected], or via fax at 949-367-9984.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.